People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Janux Therapeutics, Inc. | — | Biotechnology | Series D+ | $192.4M | $4.0B | 2020 |
| Valora Therapeutics, Inc. | — | Biotechnology | Series A | $13.0M | $67.7M | 2024 |
Stefan Heller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stefan Heller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tighe Reardon | 1 | 7 |
| Jay Lichter, Ph.D. | 1 | 5 |
| Sheila Gujrathi | 1 | 5 |
| Vickie L. Capps | 1 | 3 |
| Miguel Garcia-Guzman | 1 | 2 |
| Sanford Madigan | 1 | 2 |
| Jake Simson, Ph.D. | 1 | 2 |
| Peter Thompson, M.D. | 1 | 2 |
| David Campbell, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.